Venetoclax and Azacitidine in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory to Conventional Therapy

Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive hematological malignancy associated with poor prognosis and limited treatment options. No guideline-directed therapy existed until the approval of tagraxofusp in 2018 by the Food and Drug Administration. Multiple clinical trials a...

Descripción completa

Detalles Bibliográficos
Autores principales: Azad, Farhan, Zhang, Jiahua, Miranda, Clive J, Gravina, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886378/
https://www.ncbi.nlm.nih.gov/pubmed/36726910
http://dx.doi.org/10.7759/cureus.33109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886378/
https://www.ncbi.nlm.nih.gov/pubmed/36726910
http://dx.doi.org/10.7759/cureus.33109

Ejemplares similares